Synthelis

Synthelis est membre de Lyonbiopôle

General information

5 avenue du Grand Sablon

38700 La Tronche

Incorporated in: 2011/01/03

Number of employees: 9


More information

 

Main activity

Synthelis is a service provider (CRO) for recombinant protein production using a proprietary cell-free expression system. Synthelis technology and know-how address difficult-to-express proteins with standard cell-based expression systems. The major proteins concerned are membrane proteins as  well as cytotoxic proteins.  The Synthelis offering is divided up into the following areas: - Expression feasibility phase - Activity validation phase (using SPR, patch-clamp…) - Optimization phase to improve activity levels or purity rates - Scale-up of production (several milligrams / month)Synthelis is also developing new approaches for protein therapy and vaccine development based on membrane protein delivery by liposomal vectors.


Funding

Looking for funding: Yes

Nature of funding searches:   -       Business Angels x -       ISF Funds x -       Holding   -       Seed Capital -       Venture Capital x -       Capital development x  -       Others x

Private funding obtained: Regional funds and Angels: 610 000€  in 2013

Public funding obtained: Concours national: 170 000€ in 2010 Loan from Réseau Entreprendre Isère : 25 000€, May 2011 Inovizi loan : 50 000€, May 2011

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Immune, AutoIm & Inflam. diseases - Infectiology - Parasitology - Oncology


Activities
Therapeutics, Pharma or Biotech - CRO


Technologies
Analytical & Diagnostic services - Drug delivery device - services - Antibodies - Protein - Peptide